v3 Chapter 763： Potential is not inferior to Johnson's goal

In San Francisco's venture capital circle, Genentech has a very good reputation. After all, it only took less than four years, and its valuation soared from 400,000 US dollars to more than 100 million US dollars, and it was also on the track of going public.

It can be said that if you don't know Genentech, you are not qualified to say that you are a practitioner in the venture capital industry.

But when Polaris Capital strongly acquired Genentech and the news of the suspension of the listing process came out, the whole circle was immediately shocked, and they asked for details.

When they learned that Polaris Capital had given a minimum valuation of US$200 million, they were all shocked by Polaris Capital’s large hand.

Of course, there are also people who are sour in their hearts secretly sarcasm that Polaris Capital is incapable of making such a high price.

But no matter what they think, at least one thing is certain.

Polaris Capital has rushed into this circle with an extremely powerful posture. All capital companies in San Francisco know that this market has another crocodile on a rampage.

What the outside world and colleagues thought, Xia Yu didn't have the mind to care about it. After finishing the acquisition of Genentech, he urged Peter Lynch to continue hiring, and then he started the second operation.

Time is urgent, he must act quickly, lest the cake is eaten by others!

This time, he intends to come up with a big one, in one fell swoop to start the reputation of Polaris Capital, and at the same time lay an Optimus Prime for his strategy in the biopharmaceutical field.

Genentech has the future.

It cost him more than 100 million U.S. dollars. According to this schedule, he wants to spend most of the money in his hands. He doesn't know that he will go to the Year of the Monkey. Only one of the giants of biopharmaceuticals can digest a little.

This goal is precisely the famous Abbott company in later generations.

In the 1980s, it was still the era of oil. Among the top ten companies in the United States, oil companies accounted for half of the country.

But in the 1990s, it will be the time when the biopharmaceutical field will explode.

It will be too late to re-enter at that time, and it is definitely an appropriate time to enter early.

Because nowadays, the biopharmaceutical field has not yet exploded. Even the giants in this industry have a low market value, not even a tens of billions of dollars.

It is worth mentioning that the company with the highest market value in the United States is IBM, the blue giant, with a market value of more than 30 billion US dollars.

Back to the topic, let's talk about the biopharmaceutical field.

At this time, there are not a few pharmaceutical giants in the United States. It is not Johnson & Johnson, who is in the first place, but Merck, which has a market value of more than 200 billion U.S. dollars, and Johnson & Johnson is second.

Next, there are companies such as Eli Lilly, Bristol-Myers Squibb, Pfizer, Wyeth, Abbott.

Yes, although Pfizer is already strong at this time, it is not the next generation of the global pharmaceutical giants, and Wyeth has not been acquired by Pfizer.

Among these companies, Xia Yu focused on Abbott, which was ranked ninth in the US pharmaceutical field at this time.

Johnson & Johnson has a market value of more than US$300 billion in future generations, which once exceeded US$400 billion, while Pfizer is also hovering at US$300 billion. It stands to reason that these two companies should have the greatest potential and should be the hunting targets.

But in fact, Xia Yu passed the two after considering it.

There is no way, behind Johnson & Johnson is a large consortium, which he can't afford to provoke. Johnson & Johnson is developing well at this time, and consortiums that don't lack money will not sell it.

As for Pfizer, the next generation of Viagra became popular globally, but it is still more than ten years before Viagra was developed.

Moreover, Xia Yu also knows that Pfizer’s future market value is very high, but that high market value is piled up with huge capital. Pfizer can sit in that position entirely through mergers and acquisitions, otherwise it will rely solely on Viagra. The medicine can't support this height.

The history of the rise of Pfizer is a history of mergers and acquisitions in the pharmaceutical field. Since 1999, Pfizer has acquired Warner Lambert, Pharmacia, and Wyeth with a large amount of money, and obtained a large number of high-quality brand-name drugs, each of which can be ordered. In the top 10 of the history of pharmaceutical companies' mergers and acquisitions, the total value is 244.1 billion US dollars!

Among them, the acquisition of Warner Lambert was the largest acquisition in the history of pharmaceuticals before Xia Yu was reborn!

Leaving aside future generations, the current Pfizer company is also immersed in diversification. It is constantly acquiring companies. From the outside world, Pfizer cannot be called a qualified pharmaceutical company.

Because Pfizer invests only 5% in scientific research, which is far less than the 9% of Merck and Johnson.

Pfizer’s sinking lasted for ten years. It was not until the lack of scientific research results and the shortcomings of new drugs became apparent, and it reinvested in the research and development of new drugs. This was the successful launch of Viagra in 1998.

So at this time, Xia Yu didn't want to mess with Pfizer.

Pfizer, which has been thinking about buying and buying, may not accept his acquisition.

In that case, why should he be thankless?

There is still a long time to come, there will always be a suitable opportunity to do it again!

As for why other companies did not choose Abbott, it was because, besides Johnson & Johnson, Abbott had the greatest potential!

In the second half of this year, Dr. George B. Latman, who worked for Abbott, will leave and create the next generation billion-dollar giant Amgen. Amgen is also one of the top ten US pharmaceutical companies.

Then in 2011, Abbott spun out an AbbVie company internally, and its market value broke through 100 billion U.S. dollars after being listed separately, making it one of the top ten pharmaceutical companies in the United States.

As for Abbott, its market value is more than 100 billion U.S. dollars. Before AbbVie, it was located in the sixth or seventh American pharmaceutical company.

Calculating carefully, Abbott, which has a market value of only 2.8 billion U.S. dollars, has been able to emerge because of it three hundred billion or more companies ~ www.novelhall.com ~ occupying three positions among the top ten pharmaceutical companies in the United States.

If the three companies add up, their market value will surpass that of Johnson & Johnson, the strongest pharmaceutical company in the United States.

And these three companies did not rise through mergers and acquisitions like Pfizer, but developed step by step. Although mergers and acquisitions will occur in the middle, they mainly engage in R&D and development.

The potential is not worse than that of Johnson & Johnson. The market value is now much lower than that of Johnson & Johnson. The point is that it is not controlled by the top ten consortia in the United States and the difficulty of acquisition is much lower than that of Johnson & Johnson.

Xia Yu would not choose it unless he was stupid!

In addition to being strong in the pharmaceutical field, Abbott is also strong in the field of milk powder, making it one of the three giants in the US milk powder market today.

In the US milk powder market, the three giants from big to small are Wyeth Group, Abbott and Mead Johnson, and the next-tier is Garbo.

Wyeth Group has overwhelmed Abbott in the pharmaceutical field or in the milk powder field, but Xia Yu did not consider acquiring Wyeth Group.

In any industry, the difficulty and cost of acquiring the second child are even smaller.

Strictly speaking, Abbott is not so much a pharmaceutical company as it is a healthcare company, because its products involve the fields of nutrition, drugs, medical devices, diagnostic instruments and reagents.

After determining the target, Xia Yu immediately convened the company's high-level meeting, once again formed the acquisition team, and made every effort to prepare the acquisition plan.

At the same time, considering the subsequent actions, the number of companies at this time is far from enough. Xia Yu once again urged Korn Ferry to hire Polaris Capital to have M&A experience in biopharmaceuticals, finance, media and high-tech fields. Of the elite.

The acquisition of Abbott is a major task, but it is definitely not the only task!

https://

Please remember the domain name of this book's first publication:. Apex novel mobile version reading URL: